Payors Without Formal Medical Policy Criteria

Autologous Chondrocyte Implantation—Pre-authorization Checklist*

The following checklist reflects common payor requirements for MACI[®] (autologous cultured chondrocytes on porcine collagen membrane). Failure to include all of this information in the pre-authorization request or failure to make sure that all 'no' answers are fully addressed in the pre-authorization request will significantly increase the likelihood that the pre-authorization request will be denied or significantly delayed.

More restrictive plans may require additional documentation to demonstrate medical necessity. Best practice is to include these items.

 Defect information should include: Treatment is for focal, full-thickness (Outerbridge Classification of Grade III or IV) lesions Documentation to consider: if bipolar lesions, why MACI is the only appropriate treatment and if concurrent processes will correct maltracking or cause of bipolar lesions Location of the defect is on the weight bearing surface of the patella, trochlear groove, or the femoral condyle (medial, lateral) Size of the defect is at least 1.5 cm² 	🗆 Yes 🗖 No
 Patient Information should include: BMI is less than or equal to 35 Patient aged 15-55 years old If under 18 years old, documented closure of growth plates Function-limiting pain Documentation to consider: function-limiting pain of ≥ 3/10 and interferes with knee function in 2 areas of activities of daily living Capable of cooperating with post-operative weight bearing restrictions and completion of post-operative rehabilitation. Failure of previous treatment Inadequate response to a prior arthroscopic or other surgical repair procedure (e.g., debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft Documentation to consider: failure of provider-directed, non-surgical/conservative treatment for at least three (3) months including physical therapy or compliance with a physician directed HEP 	□ Yes □ No
 Physical examination findings should include the following: A stable knee with intact or reconstructed ligaments (ACL or PCL) OR ligamentous issues that will be addressed concomitantly Normal tibial-femoral and/or patella-femoral alignment OR will be addressed concomitantly Minimal to absent degenerative changes in the surrounding articular cartilage (Outerbridge Grade II or less) and normal-appearing hyaline cartilage surrounding the border of the defect 	🗆 Yes 🗖 No
 Confirm absence of: Moderate-severe OA of the knee, generalized tibial chondromalacia, and inflammatory arthritis or other systemic disease affecting the joints Any indication not listed above. Treatment of joints other than the knee (e.g., shoulder, hip, tibia, talus, glenohumeral) History of total meniscectomy (≥50% meniscus remains intact) A cartilaginous defect (related to osteoarthritis, rheumatoid arthritis or inflammatory diseases) or where an osteoarthritic or inflammatory process unfavorably affects peri-lesional cartilage quality Osteochondritis dissecans Contraindications Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin. Severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease Presence of cancer/malignancy in area of treatment Uncorrected congenital blood coagulation disorders. Prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant. Individual is unable to follow a physician-prescribed post-surgical rehabilitation program. 	□ Yes □ No

All 'no' answers must be fully addressed at time of pre-authorization.

The reimbursement material contained in this guide represents our current (as of January 2024) understanding of the pre-authorization checklists reflected in various payer policies. Many of the topics covered in this guide are complex and all are subject to change beyond our control. Healthcare professionals are responsible for keeping current and complying with reimbursement-related rules and regulations. Nothing contained herein is intended, nor should it be construed as, to suggest a guarantee of coverage or reimbursement for any product or service. Check with the individual insurance provider regarding coverage. Providers should exercise independent clinical judgment when submitting claims to reflect accurately the services rendered to individual patients.